Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 21, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2026

Conditions
Chemotherapy Induced Neuropathic Pain
Interventions
DRUG

Halneuron

Halneuron for Subcutaneous Injection

DRUG

Placebo

Placebo for Subcutaneous Injection

Trial Locations (19)

11530

RECRUITING

Rubin MD, Garden City

14221

RECRUITING

Upstate Clinical Research Associates LLC, Williamsville

30331

RECRUITING

CenExel ACMR, Atlanta

32832

RECRUITING

Conquest Research LLC, Orlando

33613

RECRUITING

CenExel FCR, Tampa

33812

RECRUITING

TOI Clinical Research, Lakeland

33952

RECRUITING

Medsol Clinical Research Center, Inc, Port Charlotte

48334

RECRUITING

Profound Research at OMG Division of Clinical Hematology and Medical Oncology, Farmington

53715

RECRUITING

SSM Health Dean Medical Group, Madison

63026

RECRUITING

Circuit Clinical/ SSM St. Clare Cancer Care, Fenton

64111

RECRUITING

Saint Lukes Hospital, Kansas City

77030

RECRUITING

Center for Oncology and Blood Disorders, Houston

80033

RECRUITING

Paradigm Clinical Research, Wheat Ridge

84107

RECRUITING

CenExel JBR, Salt Lake City

89109

RECRUITING

Exel Clinical Research, Las Vegas

91105

RECRUITING

Profound Research LLC, Pasadena

92708

RECRUITING

Ark Clinical Research, Fountain Valley

95403

RECRUITING

Providence Medical Foundation, Santa Rosa

95628

RECRUITING

APEX Research Group, LLC, Fair Oaks

Sponsors
All Listed Sponsors
lead

Dogwood Therapeutics Inc.

INDUSTRY